Evidence map›Paper›PMID 35173012›Full record

Observational studyBMJ open2022

The Childhood Cancer Diagnosis (CCD) Study: a UK observational study to describe referral pathways and quantify diagnostic intervals in children and young people with cancer.

Dhurgshaarna Shanmugavadivel, Jo-Fen Liu, Ashley Ball-Gamble, Angela Polanco, Kavita Vedhara, David Walker, Shalini Ojha

Open access · goldAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in BMJ open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Dhurgshaarna ShanmugavadivelAcademic Unit of Population and Lifespan Sciences, University of Nottingham Faculty of Medicine and Health Sciences, Nottingham, UK shaarnashan@doctors.org.uk.ORCID 0000-0002-1912-4543
Jo-Fen LiuAcademic Unit of Population and Lifespan Sciences, University of Nottingham Faculty of Medicine and Health Sciences, Nottingham, UK.ORCID 0000-0001-5796-7878
Ashley Ball-GambleChief Executive Office, Children's Cancer and Leukaemia Group, Leicester, UK.ORCID 0000-0002-0708-0918
Angela PolancoChief Executive Office, Children's Cancer and Leukaemia Group, Leicester, UK.ORCID 0000-0002-4619-0773
Kavita VedharaAcademic Unit of Population and Lifespan Sciences, University of Nottingham Faculty of Medicine and Health Sciences, Nottingham, UK.ORCID 0000-0002-9940-7534
David WalkerChildren's Brain Tumour Research Centre, University of Nottingham, Nottingham, UK.
Shalini OjhaAcademic Unit of Population and Lifespan Sciences, University of Nottingham Faculty of Medicine and Health Sciences, Nottingham, UK.ORCID 0000-0001-5668-4227
University of Nottingham · GBChildren's Cancer and Leukaemia Group · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionChildhood cancer is diagnosed in 400 000 children and young people (CYP) aged 0-19 years worldwide annually. In the UK, a child's cumulative cancer risk increases from 1 in 4690 from birth to aged 1, to 1 in 470 by age 15. Once diagnosed, access to treatments offers survival to adulthood for over 80%. Tumour diagnoses are at a later stage and mortality is higher when compared with those in other parts of Europe. This means higher risk, more intensive therapies for a cure. Some CYPs are known to experience delays to diagnosis which may further contribute to poor outcomes. This study aims to understand the current pathway of childhood cancer referrals and diagnosis and quantify diagnostic intervals in the UK. METHODS AND ANALYSIS: This is a prospective multicentre observational study including all tertiary childhood cancer treatment centres in the UK. CYP (0-18 years) with a new diagnosis of cancer over the study period will be invited to participate. Data will be collected at initial diagnosis and 5 years after diagnosis. Data will include demographic details, clinical symptoms, tumour location, stage and clinical risk group. In addition, key diagnostic dates and referral routes will be collected to calculate the diagnostic intervals. At 5 years' follow-up, data will be collected on refractory disease, relapse and 1-year and 5-year survival. Population characteristics will be presented with descriptive analyses with further analyses stratified by age, geographical region and cancer type. Associations between diagnostic intervals/delay and risk factors will be explored using multiple regression and logistic regression. ETHICS: The study has favourable opinion from the York and Humber, Leeds West REC (19/YH/0416). DISSEMINATION: Results will be presented at academic conferences, published in peer-reviewed journals and disseminated through public messaging in collaboration with our charity partners through a national awareness campaign (ChildCancerSmart). STUDY REGISTRATION: researchregistry.com (researchregistry5313).

Indexed as

NeoplasmsAdolescentAdultChildEuropeHumansProspective StudiesReferral and ConsultationUnited Kingdomepidemiologypaediatric oncologypublic health

Identifiers

PMID35173012
PMCPMC8852751
OpenAlexW4213388142

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.